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Benign prostate hyperplasia (BPH), a condition of the prostate common in aging in men, 
is associated with urinary voiding dysfunction, or Lower Urinary Tract Symptoms (LUTS). 
Although inflammation and abnormal muscle contraction are known to be key players in 
the development of LUTS, tissue fibrosis may also be an important and previously 
unrecognized contributing factor. Tissue fibrosis arises from the differentiation of 
fibroblasts into myofibroblasts, which produce and secrete collagens and fibronectins 
that remodel the extracellular matrix  (ECM). This differentiation process is usually 
accomplished by activation of the TGF-β/TGFβRII axis. However, in this study we report 
that the CXC-type chemokine, CXCL12, and its receptor, CXCR4, which are up-
regulated with aging in the prostate, can drive this differentiation process as well. We 
have observed that CXCL12 can promote myofibroblast phenoconversion in the 
absence of exogenous TGF-β and can up-regulate the expression of myofibroblast 
genes (α-SMA, COL1, TGF-β) in primary and immortalized prostate fibroblasts. Recently 
we discovered that the activated CXCL12/CXCR4 axis signals through the EGFR and 
through downstream MEK/ERK and Akt pathways during myofibroblast differentiation, 
but not through Smad proteins.  Smad proteins are the primary signaling proteins utilized 
by the TGFβRII. This suggests that CXCL12/CXCR4-mediated signaling events in 
prostate myofibroblast phenoconversion may proceed through non-canonical pathways 
that do not depend on TGF-β/TGFβRII axis activation or Smad signaling. Furthermore, 
we observed significant reduction in the activation of EGFR and ERK pathways when 
treating fibroblasts with an EGFR inhibitor as well as a pan-Metalloprotease inhibitor 
previous to chemokine treatment. Conversely, chemical inhibition of TGF-βRII or Smad3 
activation did not prevent CXCL12-mediated EGFR, MEK/ERK activation or 
myofibroblast phenoconversion. Based on these findings, we hypothesize that EGFR 
activation by CXCL12/CXCR4 might be required for ERK and Akt activation during 
myofibroblasts conversion, and may be coupled to the shedding of extracellular ligands 
of EGFR by extracellular proteases. 
 
